EE05427B1 - 6-asendis asendatud indolinoonid, nende valmistamine ja nende kasutamine ravimitena - Google Patents

6-asendis asendatud indolinoonid, nende valmistamine ja nende kasutamine ravimitena

Info

Publication number: EE05427B1
Authority: EE; Estonia
Prior art keywords: medicaments; preparation; substituted indolinones; indolinones; substituted
Prior art date: 1999-10-13

Application number

EEP200200197A

Other languages

English (en)

Inventor

Heckel Armin

J�rgen Roth Gerald

Walter Rainer

C. A. Van Meel Jacobus

Redemann Norbert

Tontsch-Grunt Ulrike

Spevak Walter

Hilberg Frank

Original Assignee

Boehringer Ingelheim Pharma Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-13

Filing date

2000-10-09

Publication date

2011-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05427(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-10-13 Priority claimed from DE19949208A external-priority patent/DE19949208A1/de

2000-08-31 Priority claimed from DE2000142696 external-priority patent/DE10042696A1/de

2000-10-09 Application filed by Boehringer Ingelheim Pharma Kg filed Critical Boehringer Ingelheim Pharma Kg

2003-06-16 Publication of EE200200197A publication Critical patent/EE200200197A/et

2011-06-15 Publication of EE05427B1 publication Critical patent/EE05427B1/et

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EEP200200197A 1999-10-13 2000-10-09 6-asendis asendatud indolinoonid, nende valmistamine ja nende kasutamine ravimitena EE05427B1 (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19949208A DE19949208A1 (de)	1999-10-13	1999-10-13	In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE2000142696 DE10042696A1 (de)	2000-08-31	2000-08-31	In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/009867 WO2001027081A1 (de)	1999-10-13	2000-10-09	In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel

Publications (2)

Publication Number	Publication Date
EE200200197A EE200200197A (et)	2003-06-16
EE05427B1 true EE05427B1 (et)	2011-06-15

Family

ID=26006858

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200197A EE05427B1 (et)	1999-10-13	2000-10-09	6-asendis asendatud indolinoonid, nende valmistamine ja nende kasutamine ravimitena

Country Status (42)

Country	Link
EP (2)	EP1224170B9 (et)
JP (2)	JP4021664B2 (et)
KR (2)	KR100857734B1 (et)
CN (1)	CN100455568C (et)
AR (1)	AR026036A1 (et)
AT (1)	ATE439342T1 (et)
AU (1)	AU781939B2 (et)
BE (1)	BE2015C018I2 (et)
BG (1)	BG65983B1 (et)
BR (1)	BRPI0014735B8 (et)
CA (1)	CA2387013C (et)
CO (1)	CO5261488A1 (et)
CY (2)	CY1110067T1 (et)
CZ (1)	CZ301073B6 (et)
DE (1)	DE50015711D1 (et)
DK (1)	DK1224170T5 (et)
EA (1)	EA006080B1 (et)
EE (1)	EE05427B1 (et)
EG (1)	EG25931A (et)
ES (1)	ES2331459T3 (et)
FR (1)	FR15C0024I2 (et)
HK (1)	HK1052505B (et)
HR (1)	HRP20020306B1 (et)
HU (2)	HU230416B1 (et)
IL (2)	IL148756A0 (et)
LU (1)	LU92681I2 (et)
ME (1)	MEP45408A (et)
MX (1)	MXPA02002799A (et)
MY (1)	MY127956A (et)
NL (1)	NL300725I2 (et)
NO (3)	NO322746B1 (et)
NZ (1)	NZ518489A (et)
PE (1)	PE20010671A1 (et)
PL (1)	PL207445B1 (et)
PT (1)	PT1224170E (et)
RS (1)	RS51013B (et)
SA (1)	SA01210704B1 (et)
SI (1)	SI1224170T1 (et)
SK (1)	SK287312B6 (et)
TW (1)	TWI268922B (et)
UA (1)	UA75054C2 (et)
WO (1)	WO2001027081A1 (et)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19816624A1 (de) *	1998-04-15	1999-10-21	Boehringer Ingelheim Pharma	Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
KR100589032B1 (ko)	2000-10-20	2006-06-14	에자이 가부시키가이샤	질소 함유 방향환 유도체
US6638965B2 (en)	2000-11-01	2003-10-28	Boehringer Ingelheim Pharma Kg	Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de)	2001-04-06	2002-10-10	Boehringer Ingelheim Pharma	In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US20030091974A1 (en) *	2001-06-29	2003-05-15	Alain Moussy	Method for screening compounds capable of depleting mast cells
JP2004537537A (ja)	2001-06-29	2004-12-16	アブサイエンス	炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
WO2003002106A2 (en)	2001-06-29	2003-01-09	Ab Science	Use of tyrosine kinase inhibitions for treating allergic diseases
ATE343415T1 (de)	2001-06-29	2006-11-15	Ab Science	Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
DE60227709D1 (de) *	2001-06-29	2008-08-28	Ab Science	Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
US7727731B2 (en)	2001-06-29	2010-06-01	Ab Science	Potent, selective and non toxic c-kit inhibitors
CA2461812C (en) *	2001-09-27	2011-09-20	Allergan, Inc.	3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
US6797825B2 (en)	2001-12-13	2004-09-28	Abbott Laboratories	Protein kinase inhibitors
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
EP1458713B1 (en)	2001-12-27	2005-08-24	Theravance, Inc.	Indolinone derivatives useful as protein kinase inhibitors
SE0302546D0 (sv)	2003-09-24	2003-09-24	Astrazeneca Ab	New compounds
ITBO20020198A1 (it) *	2002-04-12	2003-10-13	Univ Bologna	Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed
US7169936B2 (en)	2002-07-23	2007-01-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en)	2002-07-23	2009-04-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
DE10233500A1 (de) *	2002-07-24	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en)	2002-08-16	2004-10-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de)	2002-08-16	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US7148249B2 (en) *	2002-09-12	2006-12-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) *	2002-11-27	2012-02-22	アラーガン、インコーポレイテッド	疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005044788A1 (ja)	2003-11-11	2005-05-19	Eisai Co., Ltd.	ウレア誘導体およびその製造方法
SE0401790D0 (sv) *	2004-07-07	2004-07-07	Forskarpatent I Syd Ab	Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
EP2364699A1 (en)	2004-09-13	2011-09-14	Eisai R&D Management Co., Ltd.	Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en)	2004-09-13	2014-07-08	Eisai R&D Management Co., Ltd.	Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
AU2005283422C1 (en)	2004-09-17	2017-02-02	Eisai R & D Management Co., Ltd.	Medicinal composition
PE20060777A1 (es) *	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2281901B1 (en)	2005-08-02	2013-11-27	Eisai R&D Management Co., Ltd.	Anti-tumour pharmaceutical composition with angiogenesis inhibitors
WO2007057397A1 (en) *	2005-11-15	2007-05-24	Boehringer Ingelheim International Gmbh	Treatment of cancer
CN104706637A (zh)	2006-05-18	2015-06-17	卫材R&D管理有限公司	针对甲状腺癌的抗肿瘤剂
EP1870400A1 (en) *	2006-06-08	2007-12-26	Boehringer Ingelheim Pharma GmbH & Co. KG	Salts and crystalline salt forms of an 2-indolinone derivative
KR101472600B1 (ko)	2006-08-28	2014-12-15	에자이 알앤드디 매니지먼트 가부시키가이샤	미분화형 위암에 대한 항종양제
JP5319306B2 (ja)	2007-01-29	2013-10-16	エーザイ・アール・アンド・ディー・マネジメント株式会社	未分化型胃癌治療用組成物
WO2008152013A1 (en) *	2007-06-12	2008-12-18	Boehringer Ingelheim International Gmbh	Indolinone derivatives and their use in treating disease-states such as cancer
ES2435454T3 (es)	2007-06-21	2013-12-19	Janssen Pharmaceutica, N.V.	Indolin-2-onas y aza-indolin-2-onas
KR101513326B1 (ko)	2007-11-09	2015-04-17	에자이 알앤드디 매니지먼트 가부시키가이샤	혈관 신생 저해 물질과 항종양성 백금 착물의 병용
PE20091445A1 (es) *	2007-12-03	2009-10-19	Boehringer Ingelheim Int	Derivados de indolinona y procedimiento para su fabricacion
CN101883756A (zh)	2007-12-03	2010-11-10	贝林格尔.英格海姆国际有限公司	制备二氢吲哚酮衍生物的方法
ES2662824T3 (es)	2008-06-06	2018-04-09	Boehringer Ingelheim International Gmbh	Combinación farmacéutica
EP2471787A1 (en)	2008-07-29	2012-07-04	Boehringer Ingelheim International GmbH	New compounds
JP2012515184A (ja)	2009-01-14	2012-07-05	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	大腸がんの治療方法
US8802384B2 (en)	2009-03-12	2014-08-12	Boehringer Ingelheim International Gmbh	Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en)	2009-03-24	2010-09-30	Life & Brain Gmbh	Promotion of neuronal integration in neural stem cell grafts
EP2429520A1 (en)	2009-05-14	2012-03-21	Boehringer Ingelheim International GmbH	New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en)	2010-04-27	2012-05-03	Boehringer Ingelheim International Gmbh	Combination therapy in treatment of oncological and fibrotic diseases
JP5898074B2 (ja)	2010-06-25	2016-04-06	エーザイ・アール・アンド・ディー・マネジメント株式会社	キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
WO2012068441A2 (en)	2010-11-19	2012-05-24	Ratiopharm Gmbh	Intedanib salts and solid state forms thereof
KR101762999B1 (ko)	2011-04-18	2017-07-28	에자이 알앤드디 매니지먼트 가부시키가이샤	종양 치료제
EP3444363B1 (en)	2011-06-03	2020-11-25	Eisai R&D Management Co., Ltd.	Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
EP3604307A1 (en)	2012-01-26	2020-02-05	Angion Biomedica Corp.	Anti-fibrotic compounds and uses thereof
CA2890346A1 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
EP2914621B1 (en)	2012-11-05	2023-06-07	Foundation Medicine, Inc.	Novel ntrk1 fusion molecules and uses thereof
CN104936944B (zh) *	2012-12-06	2017-09-12	山东亨利医药科技有限责任公司	作为酪氨酸激酶抑制剂的吲哚满酮衍生物
MX2015004979A (es)	2012-12-21	2015-07-17	Eisai R&D Man Co Ltd	Forma amorfa de derivado de quinolina y metodo para su produccion.
WO2014113729A2 (en)	2013-01-18	2014-07-24	Foundation Mecicine, Inc.	Methods of treating cholangiocarcinoma
US20140350022A1 (en)	2013-05-10	2014-11-27	Boehringer Ingelheim International Gmbh	Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
SG11201509278XA (en)	2013-05-14	2015-12-30	Eisai R&D Man Co Ltd	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104003925B (zh) *	2013-06-05	2016-03-30	四川大学	吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) *	2013-07-18	2015-01-22	Concert Pharmaceuticals, Inc.	Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015017728A1 (en)	2013-07-31	2015-02-05	Windward Pharma, Inc.	Aerosol tyrosine kinase inhibitor compounds and uses thereof
RS63559B1 (sr)	2014-08-28	2022-10-31	Eisai R&D Man Co Ltd	Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
CN104262232B (zh) *	2014-09-09	2016-05-04	苏州明锐医药科技有限公司	尼泰达尼的制备方法
SG11201706630UA (en)	2015-02-25	2017-09-28	Eisai R&D Man Co Ltd	Method for suppressing bitterness of quinoline derivative
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016178064A1 (en)	2015-05-06	2016-11-10	Suven Life Sciences Limited	Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (zh) *	2015-06-05	2017-03-08	北京康立生医药技术开发有限公司	一锅法制备尼达尼布的合成方法
EP4335418A3 (en)	2015-06-06	2024-05-22	Cloudbreak Therapeutics, LLC	Compositions and methods for treating pterygium
CA2988707C (en)	2015-06-16	2023-10-10	Eisai R&D Management Co., Ltd.	Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN105126909B (zh) *	2015-07-13	2018-01-23	淮海工学院	固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CZ308695B6 (cs)	2015-07-29	2021-03-03	Zentiva, K.S.	Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)
CN106467500A (zh) *	2015-08-14	2017-03-01	廊坊百瑞化工有限公司	一种一锅煮法合成尼达尼布关键中间体的新方法
RU2718048C2 (ru)	2015-08-20	2020-03-30	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое терапевтическое средство
CN109302846B (zh)	2015-12-24	2021-05-11	莱斯彼维特有限公司	吲哚啉酮化合物及其在纤维化疾病治疗中的用途
CZ2016104A3 (cs)	2016-02-24	2017-09-06	Zentiva, K.S.	Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
AU2017231860C1 (en)	2016-03-08	2022-01-20	Respivert Limited	Indole derivatives and their use as protein kinase inhibitors
WO2017178428A1 (en)	2016-04-13	2017-10-19	Boehringer Ingelheim International Gmbh	Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en)	2016-05-19	2017-11-22	Boehringer Ingelheim International Gmbh	Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
US20190275032A1 (en)	2016-05-27	2019-09-12	Boehringer Ingelheim International Gmbh	Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone
WO2017207643A1 (en)	2016-06-01	2017-12-07	Boehringer Ingelheim International Gmbh	Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
AU2017274195B2 (en)	2016-06-02	2022-04-07	Ads Therapeutics Llc	Compositions and methods of using nintedanib for improving glaucoma surgery success
CN109789127B (zh)	2016-07-29	2022-03-25	英克特诺治疗公司	吲哚啉酮化合物的用途
CN106748961A (zh) *	2016-11-30	2017-05-31	瑞阳制药有限公司	尼达尼布的杂质化合物、制备方法、应用及其检测方法
CN106748960A (zh) *	2016-11-30	2017-05-31	瑞阳制药有限公司	尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法
WO2018108669A1 (en)	2016-12-12	2018-06-21	Boehringer Ingelheim International Gmbh	Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
EP3600322A1 (en)	2017-03-28	2020-02-05	Boehringer Ingelheim International GmbH	Nintedanib for use in methods for the treatment of muscular dystrophy
MA50441A (fr)	2017-10-23	2020-09-02	Boehringer Ingelheim Int	Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild)
US11261158B2 (en)	2017-11-17	2022-03-01	Fermion Oy	Synthesis of 2-indolinone derivatives
JP7061310B2 (ja) *	2018-04-05	2022-04-28	国立大学法人大分大学	慢性脂肪性疾患の予防および治療用医薬
CN108358827A (zh) *	2018-05-07	2018-08-03	日照市普达医药科技有限公司	一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法
US12156873B2 (en)	2018-05-25	2024-12-03	Ads Therapeutics Llc	Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
MX2021003945A (es) *	2018-10-05	2021-05-27	Ichnos Sciences S A	Compuestos de indolinona para uso como inhibidores de map4k1.
CN115361950A (zh)	2020-04-01	2022-11-18	勃林格殷格翰国际有限公司	生物标记物在治疗纤维化病症中的用途
CN111848490B (zh) *	2020-08-24	2021-09-24	江西国药有限责任公司	一种高纯度乙磺酸尼达尼布的制备方法
CN112574094B (zh) *	2020-12-14	2022-07-01	成都大学	吲哚酮衍生物及其制药用途
WO2022158956A1 (ko)	2021-01-25	2022-07-28	주식회사 나이벡	섬유화 예방 및 치료용 펩타이드
EP4098246A1 (en)	2021-05-31	2022-12-07	Lotus Pharmaceutical Co., Ltd.	Formulation of nintedanib
CN115703758B (zh) *	2021-08-12	2024-03-26	中国医学科学院药物研究所	一类用作激酶抑制剂的化合物及其制备方法和用途
WO2024037982A1 (en)	2022-08-16	2024-02-22	Boehringer Ingelheim International Gmbh	Pharmaceutical formulations of nintedanib for intraocular use
TWI857798B (zh) *	2023-09-28	2024-10-01	國立臺灣大學	用於治療及/或預防腫瘤或細胞增生及纖維化疾病之吲哚啉衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL96047C (et) *	1956-06-08
WO1995030420A1 (en) *	1994-05-06	1995-11-16	Alcon Laboratories, Inc.	Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
ATE243034T1 (de) *	1996-01-17	2003-07-15	Taiho Pharmaceutical Co Ltd	Intimale verdickungsinhibitoren
GB9718913D0 (en) *	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
DE19815020A1 (de) *	1998-04-03	1999-10-07	Boehringer Ingelheim Pharma	Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19816624A1 (de) *	1998-04-15	1999-10-21	Boehringer Ingelheim Pharma	Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19824922A1 (de) *	1998-06-04	1999-12-09	Boehringer Ingelheim Pharma	Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) *	1999-03-04	1999-04-28	Glaxo Group Ltd	Compounds

2000
- 2000-09-10 UA UA2002053890A patent/UA75054C2/uk unknown
- 2000-10-09 HU HU0204587A patent/HU230416B1/hu active Protection Beyond IP Right Term
- 2000-10-09 EE EEP200200197A patent/EE05427B1/et active Protection Beyond IP Right Term
- 2000-10-09 MX MXPA02002799A patent/MXPA02002799A/es active IP Right Grant
- 2000-10-09 DK DK00971347.0T patent/DK1224170T5/en active
- 2000-10-09 RS YUP-266/02A patent/RS51013B/sr unknown
- 2000-10-09 AU AU10233/01A patent/AU781939B2/en active Active
- 2000-10-09 SK SK646-2002A patent/SK287312B6/sk not_active IP Right Cessation
- 2000-10-09 ES ES00971347T patent/ES2331459T3/es not_active Expired - Lifetime
- 2000-10-09 CZ CZ20021410A patent/CZ301073B6/cs unknown
- 2000-10-09 CN CNB008158681A patent/CN100455568C/zh not_active Expired - Lifetime
- 2000-10-09 BR BRPI0014735 patent/BRPI0014735B8/pt active IP Right Grant
- 2000-10-09 EP EP00971347.0A patent/EP1224170B9/de not_active Expired - Lifetime
- 2000-10-09 SI SI200031039T patent/SI1224170T1/sl unknown
- 2000-10-09 AT AT00971347T patent/ATE439342T1/de active
- 2000-10-09 PT PT00971347T patent/PT1224170E/pt unknown
- 2000-10-09 EA EA200200380A patent/EA006080B1/ru not_active IP Right Cessation
- 2000-10-09 EP EP09164507A patent/EP2157081A1/de not_active Withdrawn
- 2000-10-09 CA CA002387013A patent/CA2387013C/en not_active Expired - Lifetime
- 2000-10-09 KR KR1020077017807A patent/KR100857734B1/ko active IP Right Grant
- 2000-10-09 NZ NZ518489A patent/NZ518489A/en not_active IP Right Cessation
- 2000-10-09 IL IL14875600A patent/IL148756A0/xx active IP Right Grant
- 2000-10-09 ME MEP-454/08A patent/MEP45408A/xx unknown
- 2000-10-09 JP JP2001530102A patent/JP4021664B2/ja not_active Expired - Lifetime
- 2000-10-09 DE DE50015711T patent/DE50015711D1/de not_active Expired - Lifetime
- 2000-10-09 WO PCT/EP2000/009867 patent/WO2001027081A1/de active IP Right Grant
- 2000-10-09 KR KR1020027004701A patent/KR100835546B1/ko active IP Right Grant
- 2000-10-09 PL PL355433A patent/PL207445B1/pl not_active IP Right Cessation
- 2000-10-11 PE PE2000001088A patent/PE20010671A1/es not_active IP Right Cessation
- 2000-10-11 EG EG2000101293A patent/EG25931A/xx active
- 2000-10-11 MY MYPI20004762A patent/MY127956A/en unknown
- 2000-10-12 TW TW089121320A patent/TWI268922B/zh active
- 2000-10-12 CO CO00077925A patent/CO5261488A1/es not_active Application Discontinuation
- 2000-10-13 AR ARP000105394A patent/AR026036A1/es active Pending
2001
- 2001-02-06 SA SA01210704A patent/SA01210704B1/ar unknown
2002
- 2002-03-19 IL IL148756A patent/IL148756A/en active Protection Beyond IP Right Term
- 2002-04-05 BG BG106587A patent/BG65983B1/bg active Active
- 2002-04-10 HR HR20020306A patent/HRP20020306B1/xx not_active IP Right Cessation
- 2002-04-11 NO NO20021719A patent/NO322746B1/no active Protection Beyond IP Right Term
2003
- 2003-06-30 HK HK03104649.4A patent/HK1052505B/zh not_active IP Right Cessation
2007
- 2007-08-15 JP JP2007211755A patent/JP2007302697A/ja active Pending
2009
- 2009-11-06 CY CY20091101152T patent/CY1110067T1/el unknown
2015
- 2015-03-13 CY CY2015009C patent/CY2015009PI2/el unknown
- 2015-03-16 FR FR15C0024C patent/FR15C0024I2/fr active Active
- 2015-03-16 LU LU92681C patent/LU92681I2/xx unknown
- 2015-03-16 BE BE2015C018C patent/BE2015C018I2/fr unknown
- 2015-03-16 NL NL300725C patent/NL300725I2/nl unknown
- 2015-03-18 NO NO2015009C patent/NO2015009I1/no unknown
2016
- 2016-05-13 HU HUS1600022C patent/HUS1600022I1/hu unknown
2023
- 2023-09-05 NO NO2023033C patent/NO2023033I1/no unknown

Also Published As

Publication number	Publication date
BRPI0014735B1 (pt)	2012-07-10
AU781939B2 (en)	2005-06-23
UA75054C2 (uk)	2006-03-15
NO2015009I2 (et)	2015-03-18
NO20021719D0 (no)	2002-04-11
HUS1600022I1 (hu)	2017-02-28
HK1052505B (zh)	2009-06-26
ES2331459T3 (es)	2010-01-05
NO20021719L (no)	2002-04-11
HRP20020306A2 (en)	2003-10-31
KR20020038949A (ko)	2002-05-24
AU1023301A (en)	2001-04-23
EP2157081A1 (de)	2010-02-24
CZ301073B6 (cs)	2009-10-29
FR15C0024I2 (fr)	2016-08-26
PT1224170E (pt)	2009-10-01
MEP45408A (en)	2011-02-10
EP1224170A1 (de)	2002-07-24
HK1052505A1 (en)	2003-09-19
DK1224170T3 (da)	2009-12-07
NL300725I2 (nl)	2017-07-13
WO2001027081A1 (de)	2001-04-19
BG106587A (bg)	2003-01-31
KR100857734B1 (ko)	2008-09-10
JP2007302697A (ja)	2007-11-22
DK1224170T5 (en)	2018-01-22
HUP0204587A2 (en)	2003-05-28
CN100455568C (zh)	2009-01-28
KR20070095996A (ko)	2007-10-01
EA200200380A1 (ru)	2002-10-31
CY1110067T1 (el)	2015-01-14
NZ518489A (en)	2005-05-27
HU230416B1 (hu)	2016-05-30
CY2015009PI1 (el)	2016-12-14
JP2003511441A (ja)	2003-03-25
PE20010671A1 (es)	2001-06-28
SK6462002A3 (en)	2002-08-06
LU92681I9 (et)	2019-01-03
AR026036A1 (es)	2002-12-26
HUP0204587A3 (en)	2004-07-28
KR100835546B1 (ko)	2008-06-09
IL148756A0 (en)	2002-09-12
EP1224170B1 (de)	2009-08-12
EE200200197A (et)	2003-06-16
JP4021664B2 (ja)	2007-12-12
SK287312B6 (sk)	2010-06-07
CN1391557A (zh)	2003-01-15
EP1224170B9 (de)	2017-11-22
PL355433A1 (en)	2004-04-19
CZ20021410A3 (cs)	2002-07-17
HRP20020306B1 (en)	2010-09-30
EG25931A (en)	2012-10-24
LU92681I2 (fr)	2015-05-18
PL207445B1 (pl)	2010-12-31
BG65983B1 (bg)	2010-08-31
MXPA02002799A (es)	2003-02-27
EA006080B1 (ru)	2005-08-25
YU26602A (sh)	2004-11-25
BE2015C018I2 (et)	2019-10-23
ATE439342T1 (de)	2009-08-15
CO5261488A1 (es)	2003-03-31
RS51013B (sr)	2010-10-31
NO322746B1 (no)	2006-12-04
CA2387013A1 (en)	2001-04-19
NO2023033I1 (no)	2023-09-05
SA01210704B1 (ar)	2006-12-05
IL148756A (en)	2007-10-31
CA2387013C (en)	2009-12-29
MY127956A (en)	2007-01-31
DE50015711D1 (de)	2009-09-24
BRPI0014735B8 (pt)	2021-07-06
FR15C0024I1 (et)	2015-04-17
CY2015009PI2 (el)	2016-12-14
TWI268922B (en)	2006-12-21
NO2015009I1 (no)	2015-03-30
SI1224170T1 (sl)	2009-12-31
BRPI0014735A (pt)	2002-07-16

Publication	Publication Date	Title
EE05427B1 (et)	2011-06-15	6-asendis asendatud indolinoonid, nende valmistamine ja nende kasutamine ravimitena
EE04236B1 (et)	2004-02-16	Bensimidasoolid, nende valmistamine ja kasutamineravimitena
EE05643B1 (et)	2013-04-15	Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
EE200200064A (et)	2003-04-15	Arüülmetüülkarbonüülaminotiasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena
EE04151B1 (et)	2003-10-15	Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena
EE04464B1 (et)	2005-04-15	Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200100431A (et)	2002-12-16	16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE200300048A (et)	2004-12-15	Bensimidasooli derivaadid, nende valmistamine ja terapeutiline kasutamine
EE200200175A (et)	2003-04-15	Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
EE200100470A (et)	2002-12-16	Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
NO20006138L (no)	2001-02-01	Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter
EE200200095A (et)	2003-04-15	Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
EE04565B1 (et)	2005-12-15	Adamantaani derivaadid, nende saamine ja kasutamine
EE200300311A (et)	2003-10-15	Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE200100391A (et)	2002-10-15	Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
EE200200160A (et)	2003-04-15	2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
EE200300193A (et)	2003-08-15	Asendatud bensimidasoolid, nende kasutamine ja ravim
NO20022021D0 (no)	2002-04-29	Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, fremstilling av de samme og deres anvendelse somanoreksilegemidler
DE50002417D1 (de)	2003-07-10	3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung
MXPA03000644A (es)	2003-06-06	Nuevos derivados de indol y uso como medicamentos.
HUP0201810A2 (en)	2002-09-28	Sootepenseone and its derivatives, their preparation and use as medicament
NO20014692D0 (no)	2001-09-27	3-amidinobenzensulfonamidderivater, medisinske sammensetninger inneholdende slike samt intermediater vedfremstillingen derav
ATE263138T1 (de)	2004-04-15	3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung
HUP0203557A3 (en)	2005-02-28	Novel amidine derivatives, preparation and use thereof as medicines
EE200200267A (et)	2003-06-16	Asendatud 1,2,3,4,5,6-heksahüdro-2,6-metano-3-bensasotsiinid ja nende kasutamine ravimina

Legal Events

Date	Code	Title	Description
2003-08-15	HD1A	Correction of address
2015-04-15	AA1Y	Spc filed	Free format text: PRODUCT NAME: NINTEDANIIB;REG NO/DATE: EU/1/14/954 25.11.2014 Spc suppl protection certif: C20150011 Filing date: 20150325
2015-06-15	FG1Y	Spc granted	Free format text: PRODUCT NAME: NINTEDANIIB;REG NO/DATE: EU/1/14/954 25.11.2014 Spc suppl protection certif: C20150011 00137 Filing date: 20150325 Extension date: 20251009
2023-10-16	SPCT	Party data change related to a supplementary protection certificate	Free format text: PARTY DATA CHANGE RELATED TO A GRANTED SPC Spc suppl protection certif: 000137
2024-04-15	SPCZ	Extension of supplementary protection certificate: granted [paediatric extension]	Free format text: PRODUCT NAME: NINTEDANIIB; NATIONAL AUTHORISATION NUMBER: EMA/CHMP/269668/2023 22.06.2023 Spc suppl protection certif: C20150011 Extension date: 20260409